Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ANL

Adlai Nortye Ltd. ADR

May 03 • 04:00PM ET

13.78

Dollar change +0.76
Percentage change 5.84	%

Healthcare • Biotechnology • China • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	93.71M	Perf Week	0.22%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-	Shs Float	-	Perf Month	36.98%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.07%	Short Float	-	Perf Quarter	46.75%
Sales	-	P/S	-	EPS this Y	66.80%	Inst Trans	-	Short Ratio	0.70	Perf Half Y	26.73%
Book/sh	-3.35	P/B	-	EPS next Y	-57.26%	ROA	-	Short Interest	0.01M	Perf Year	-
Cash/sh	0.64	P/C	21.51	EPS next 5Y	-	ROE	-	52W Range	7.11 - 19.30	Perf YTD	53.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-90.91%	ROI	-	52W High	-28.60%	Beta	-
Dividend TTM	-	Quick Ratio	0.16	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	93.77%	ATR (14)	1.48
Dividend Ex-Date	Aug 13, 2008	Current Ratio	0.16	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	59.08	Volatility	9.75% 16.40%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.40	Prev Close	13.02
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	8.11K	Price	13.78
SMA20	13.48%	SMA50	38.94%	SMA200	41.29%	Trades		Volume	3,247	Change	5.84%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$30

Apr-25-24 09:40AM	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-29-24 06:00AM	Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development (GlobeNewswire)
Nov-17-23 07:30AM	Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM	Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM	Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
02:46AM	Loading…
Sep-29-23 02:46AM	Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANL

Adlai Nortye Ltd. ADR

Upgrade your FINVIZ experience